Health + Tech, Investing, Startups
Volumetric to be acquired by 3D Systems ($DDD) in a deal worth up to $400M
Congratulations to the Volumetric team on their acquisition by 3D Systems!
Continue Reading >Investing
Impact Investing: Healthcare Startups vs The Stock Market
For retail investors, it has only become possible to invest in startups and private companies over the last 1-2 decades. This is largely the result of new legislation like Regulation CF and the proliferation of startup investing platforms. Prior to this, only well-connected investors with a significant net worth had the opportunity to invest in these companies.
Continue Reading >Media
The Bioverge Podcast: Evolving Failures in an Evolving Pandemic and What Needs to Be Done
Dr. Eric Topol, founder and director of the Scripps Research Translational Institute, sits down with Neil to discuss the COVID-19 delta variant, our failures to evolve with the virus, and what steps need to be taken to combat the ongoing pandemic.
Continue Reading >Media
The Bioverge Podcast: Democratizing Entrepreneurship
Juan Scarlett, managing director of OneValley Ventures, sits down with Neil to discuss OneValley's efforts to democratize entrepreneurship and his approach investing in pre-seed and seed funding rounds.
Continue Reading >Media
The Bioverge Podcast: Bridging the Translational Science Divide
Pete Schultz, CEO of Scripps Research, sits down with Neil to discuss his efforts to create a self-sustaining nonprofit drug discovery and development institute and it’s work to advance small molecule regenerative therapies from the lab to the clinic.
Continue Reading >Media
The Evolving Landscape Of Funding And Investing In Biotech Startups
The investing world is rapidly evolving.
Continue Reading >Investing
Healthcare-Focused Impact Investing: Another Way To Invest For Change
Healthcare provides another avenue in which investors can do well by doing good.
Continue Reading >Investing
Enveda Investment Thesis
Bioverge recently invested in Enveda’s $51 million Series A led by Lux Capital. Enveda is biotechnology startup focused on harnessing the power of nature’s chemistry to develop next generation small-molecule therapeutics.
Continue Reading >Press
Managed marketplaces and reality TV: How a new generation of gatekeepers is opening biotech up to amateur investors
Starton Therapeutics, a drug delivery biotech, is raising its next round of capital through Unicorn Hunters, a streaming show that invites viewers to consider and invest in a variety of startups alongside a panel of celebrity investors.
Continue Reading >Media
The Bioverge Podcast: Why the FDA Was Right to Approve Biogen's Aduhelm
James Valentine, an attorney with Hyman, Phelps & McNamara specializing in regulatory law, sits down with Neil to discuss the FDA’s accelerated approval of Biogen’s Aduhelm for Alzheimer’s disease and offers a contrarian take on the controversy.
Continue Reading >